FIRST-LINE GEFITINIB VS CARBOPLATIN/PACLITAXEL IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: PHASE III STUDY NEJ002

被引：0
|
作者：
Osamu, Ishimoto [1 ]
Kobayashi, Kunihiko [2 ]
Inoue, Akira [3 ]
Maemondo, Makoto
Sugawara, Shunichi [1 ]
Oizumi, Satoshi [4 ]
Saijo, Yasuo [5 ]
Gemma, Akihiko [6 ]
Morita, Satoshi [7 ]
Hagiwara, Koichi
Nukiwa, Toshihiro [3 ]
机构：
[1] Sendai Kosei Hosp, Sendai, Miyagi, Japan
[2] Saitama Med Univ, Int Med Ctr, Kawagoe, Saitama, Japan
[3] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[4] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan
[5] Hirosaki Univ, Sch Med, Hirosaki, Aomori, Japan
[6] Nippon Med Sch, Tokyo, Japan
[7] Yokohama City Univ, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
10.1093/annonc/mdq560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Saijo, Y.
    Genma, A.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    EJC SUPPLEMENTS, 2009, 7 (03): : 6 - 6
  • [2] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
    Miyauchi, Eisaku
    Inoue, Akira
    Kobayashi, Kunihiko
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Saijo, Yasuo
    Yoshizawa, Hirohisa
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 670 - 676
  • [3] Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Saijo, Y.
    Yoshizawa, H.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group
    Minegishi, Y.
    Inoue, A.
    Kobayashi, K.
    Gemma, A.
    Maemondo, M.
    Oizumi, S.
    Saijo, Y.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    EJC SUPPLEMENTS, 2009, 7 (04): : 25 - 25
  • [5] First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group
    Kobayashi, K.
    Inoue, A.
    Maemondo, M.
    Sugawara, S.
    Isobe, H.
    Oizumi, S.
    Saijo, Y.
    Gemma, A.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Harada, M.
    Yoshizawa, H.
    Kinoshita, I.
    Fujita, Y.
    Okinaga, S.
    Hirano, H.
    Yoshimori, K.
    Harada, T.
    Saijo, Y.
    Hagiwara, K.
    Morita, S.
    Nukiwa, T.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 54 - 59
  • [7] LONG-TERM SURVIVORS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: DATA FROM A RANDOMIZED PHASE III STUDY COMPARING GEFITINIB WITH CARBOPLATIN PLUS PACLITAXEL (NEJ002)
    Minegishi, Y.
    Kobayashi, K.
    Maemondo, M.
    Inoue, A.
    Sugawara, S.
    Oizumi, S.
    Hagiwara, K.
    Nukiwa, T.
    Morita, S.
    Gemma, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 412 - 412
  • [8] PROGNOSTIC FACTORS IN NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: DATA FROM THE RANDOMIZED PHASE III STUDY COMPARED GEFITINIB WITH CARBOPLATIN PLUS PACLITAXEL (NEJ002)
    Minegishi, Y.
    Kobayashi, K.
    Maemondo, M.
    Inoue, A.
    Sugawara, S.
    Ohizumi, S.
    Isobe, H.
    Hagiwara, K.
    Morita, S.
    Nukiwa, T.
    Gemma, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 116 - 116
  • [9] Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
    Seike, M.
    Inoue, A.
    Sugawara, S.
    Morita, S.
    Hosomi, Y.
    Ikeda, S.
    Watanabe, K.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 496 - 496
  • [10] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345